<DOC>
	<DOCNO>NCT02481830</DOCNO>
	<brief_summary>The purpose study compare overall survival nivolumab versus chemotherapy subject relapse SCLC .</brief_summary>
	<brief_title>Effectiveness Study Nivolumab Compared Chemotherapy Patients With Relapsed Small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histologically cytologically confirm small cell lung cancer ( SCLC ) Subjects either limited extensive disease stage initial diagnosis Must recurrence progression platinumbased firstline chemotherapy chemoradiation therapy treatment limit extensive disease stage SCLC Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Untreated symptomatic central nervous system ( CNS ) metastases Prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody Inadequate hematologic hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>